| European Case Law Identifier: | ECLI:EP:BA:2011:T000707.20110707 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 07 July 2011 | ||||||||
| Case number: | T 0007/07 | ||||||||
| Petition for review: | R 0018/11 | ||||||||
| Application number: | 00953387.8 | ||||||||
| IPC class: | A61K 31/565 A61K 31/585 A61P 15/00 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | ||||||||
| Applicant name: | Bayer Pharma Aktiengesellschaft | ||||||||
| Opponent name: | Hexal AG Intervener: Ladee Pharma Baltics UAB |
||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Admissibility of the appeal (yes): appellant clearly identifyable Admissibility of the intervention (no): infringement proceedings instituted in extension state not based on the European patent in suit Admissibility of auxiliary request 3 (no): prima facie clarity problems Novelty of main request and auxiliary request 1 (no): not novel over public prior use Auxiliary request 2 - Article 123(2) EPC (no): new combination of features |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t070007eu1.html
Date retrieved: 17 May 2021